Neuroendocrine Disturbances in Huntington's Disease

Background Huntington's disease (HD) is a severe inherited neurodegenerative disorder characterized, in addition to neurological impairment, by weight loss suggesting endocrine disturbances. The aims of this study were to look for neuroendocrine disturbances in patients with Huntington's disease (HD) and to determine the relationship with weight loss seen in HD Methods and Finding We compared plasma levels of hormones from the five pituitary axes in 219 patients with genetically documented HD and in 71 sex- and age-matched controls. Relationships between hormone levels and disease severity, including weight-loss severity, were evaluated. Growth hormone (GH) and standard deviation score of insulin-like growth factor 1 (SDS IGF-1) were significantly higher in patients than in controls (0.25 (0.01–5.89) vs. 0.15 (0.005–4.89) ng/ml, p = 0.013 and 0.16±1.02 vs. 0.06±0.91, p = 0.039; respectively). Cortisol was higher (p = 0.002) in patients (399.14±160.5 nmol/L vs. 279.8±130.1 nmol/L), whereas no differences were found for other hormone axes. In patients, elevations in GH and IGF-1 and decreases in thyroid-stimulating hormone, free triiodothyronine and testosterone (in men) were associated with severity of impairments (Independence scale, Functional score, Total Functional Capacity, Total Motor score, Behavioral score). Only GH was independently associated with body mass index (β = −0.26, p = 0.001). Conclusion Our data suggest that the thyrotropic and in men gonadotropic axes are altered in HD according to the severity of the disease. The somatotropic axis is overactive even in patients with early disease, and could be related to the weight loss seen in HD patients.

[1]  N. Aziz,et al.  Hypothalamic Dysfunction and Neuroendocrine and Metabolic Alterations in Huntington Disease: Clinical Consequences and Therapeutic Implications , 2007, Reviews in the neurosciences.

[2]  O. Phillipson,et al.  Plasma growth hormone concentrations in Huntington's chorea. , 1976, Clinical science and molecular medicine.

[3]  E. Guney,et al.  TSH influences serum leptin levels independent of thyroid hormones in hypothyroid and hyperthyroid patients. , 2005, Endocrine journal.

[4]  S. Doré,et al.  Rediscovering good old friend IGF-I in the new millenium: possible usefulness in Alzheimer's disease and stroke. , 2000, Pharmaceutica acta Helvetiae.

[5]  E Maran,et al.  Atrophy of the Hypothalamic Lateral Tuberal Nucleus in Huntington's Disease , 1990, Journal of neuropathology and experimental neurology.

[6]  E. J. Field,et al.  UNSATURATED FATTY ACIDS AND TRANSPLANTATION , 1975, The Lancet.

[7]  M. Panas,et al.  Plasma testosterone in male patients with Huntington's disease: Relations to severity of illness and dementia , 2005, Annals of neurology.

[8]  G. Van den Berghe Endocrine evaluation of patients with critical illness. , 2003, Endocrinology and metabolism clinics of North America.

[9]  Fabrice P Cordelières,et al.  The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt. , 2002, Developmental cell.

[10]  P. Chanson,et al.  Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a Metaanalysis of Blinded, Randomized, Placebo-Controlled Trials. , 2004, The Journal of clinical endocrinology and metabolism.

[11]  R. Chalmers,et al.  Growth hormone and prolactin response to bromocriptine in patients with Huntington's chorea. , 1978, Journal of neurology, neurosurgery, and psychiatry.

[12]  W. Tourtellotte,et al.  Growth hormone and prolactin secretion in Huntington's disease. , 1979, Life sciences.

[13]  F. Leblhuber,et al.  Serum dehydroepiandrosterone and cortisol measurements in Huntington's chorea , 1995, Journal of the Neurological Sciences.

[14]  K. Marder,et al.  Weight loss in early stage of Huntington’s disease , 2002, Neurology.

[15]  M. Hayden,et al.  IMPAIRED PROLACTIN RELEASE IN HUNTINGTON'S CHOREA EVIDENCE FOR DOPAMINERGIC EXCESS , 1977, The Lancet.

[16]  R. Ferrante,et al.  Neuropathological Classification of Huntington's Disease , 1985, Journal of neuropathology and experimental neurology.

[17]  J. Willey,et al.  PRESTROKE PHYSICAL ACTIVITY IS ASSOCIATED WITH SEVERITY AND LONG-TERM OUTCOME FROM FIRST-EVER STROKE , 2009, Neurology.

[18]  H. Lehrach,et al.  A protein interaction network links GIT1, an enhancer of huntingtin aggregation, to Huntington's disease. , 2004, Molecular cell.

[19]  I. Bone,et al.  Studies of hypothalamic function in Huntington's chorea. , 1981, Journal of neurology, neurosurgery, and psychiatry.

[20]  F. Sundler,et al.  Reduction of GnRH and infertility in the R6/2 mouse model of Huntington's disease , 2005, The European journal of neuroscience.

[21]  M. Ranke,et al.  Magnetic resonance images of 91 children with different causes of short stature: pituitary size reflects growth hormone secretion , 1997, European Journal of Pediatrics.

[22]  D. Cocchi,et al.  Altered growth hormone and prolactin responses to dopaminergic stimulation in Huntington's chorea. , 1977, The Journal of clinical endocrinology and metabolism.

[23]  S. Podolsky,et al.  Growth hormone abnormalities in Huntington's chorea: effect of L-dopa administration. , 1974, The Journal of clinical endocrinology and metabolism.

[24]  L. Murri,et al.  Circadian rhythmicity of prolactin secretion in Huntington's chorea. , 1980, Life sciences.

[25]  G. Bruyn,et al.  Pathogenesis of Huntington's chorea. , 1973, Lancet.

[26]  S. Podolsky,et al.  Exaggerated growth hormone response to arginine infusion in Huntington's disease. , 1975, The Journal of clinical endocrinology and metabolism.

[27]  P. Mantegazza,et al.  PROLACTIN CONTROL IN HUNTINGTON'S CHOREA , 1977, The Lancet.

[28]  J. Loeffler,et al.  Neuroendocrinology of Neurodegenerative Diseases , 2003, Neuroendocrinology.

[29]  R. Sapolsky,et al.  Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. , 2000, Archives of general psychiatry.

[30]  Gordon J. Gilbert WEIGHT LOSS IN HUNTINGTON DISEASE INCREASES WITH HIGHER CAG REPEAT NUMBER , 2009 .

[31]  E. Caine,et al.  Neuroendocrine function in Huntington's disease: dopaminergic regulation of prolactin release. , 1978, Life sciences.

[32]  H. Kremer,et al.  The hypothalamic lateral tuberal nucleus and the characteristics of neuronal loss in Huntington's disease , 1991, Neuroscience Letters.

[33]  H. Herken,et al.  Increased Levels of Nitric Oxide, Cortisol and Adrenomedullin in Patients with Chronic Schizophrenia , 2007, Medical Principles and Practice.

[34]  S. Folstein,et al.  Sexual disorders in Huntington's disease. , 1994, The Journal of neuropsychiatry and clinical neurosciences.

[35]  F. Casanueva,et al.  Circulating and cerebrospinal fluid ghrelin and leptin: potential role in altered body weight in Huntington's disease. , 2004, European journal of endocrinology.

[36]  Manish S. Shah,et al.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.

[37]  I. Torres-Aleman,et al.  Neurodegeneration Is Associated to Changes in Serum Insulin-like Growth Factors , 2000, Neurobiology of Disease.

[38]  H. Tanila,et al.  Orexin loss in Huntington's disease. , 2005, Human molecular genetics.

[39]  I. Heuser,et al.  The limbic-hypothalamic-pituitary-adrenal axis in Huntington's disease , 1991, Biological Psychiatry.

[40]  Jane S. Paulsen,et al.  Unified Huntington's disease rating scale: Reliability and consistency , 1996, Movement disorders : official journal of the Movement Disorder Society.

[41]  H. Fibiger,et al.  BODY WEIGHT AND DIETARY FACTORS IN HUNTINGTON'S DISEASE PATIENTS COMPARED WITH MATCHED CONTROLS , 1981, The Medical journal of Australia.

[42]  I. Shoulson,et al.  Huntington disease , 1981, Neurology.

[43]  J Kassubek,et al.  Topography of cerebral atrophy in early Huntington’s disease: a voxel based morphometric MRI study , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[44]  S. W. Davies,et al.  Formation of polyglutamine inclusions in non-CNS tissue. , 1999, Human molecular genetics.